3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
59
NIH
17
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Lung Neoplasms
5
Neuroblastoma
4
Ganglioneuroblastoma
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Medulloblastoma
3
Wilms Tumor
2
Teratoma
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Rhabdomyosarcoma, Embryonal
2
Rhabdomyosarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Mouth Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Laryngeal Neoplasms
2
Hypopharyngeal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Intraductal, Noninfiltrating
2
Carcinoma, Embryonal
2
Carcinoma
2
Burkitt Lymphoma
2
Astrocytoma
2
Uterine Cervical Neoplasms
1
Stage I Mixed Cell Type Kidney Wilms Tumor
1
Seizures
1
Sarcoma, Ewing
1
Rhabdomyosarcoma, Alveolar
1
Interventions
Radiotherapy
15
Temozolomide
14
Carmustine
6
Lomustine
3
Chemotherapy, Adjuvant
3
Bevacizumab
3
imetelstat
2
Radiosurgery
2
Radiation
2
Immunohistochemistry
2
Everolimus
2
DNA Methylation
2
vistusertib
1
veliparib
1
vatalanib
1
temsirolimus
1
sagopilone
1
rubitecan
1
palbociclib
1
mercaptoundecahydrododecaborate
1
marizomib
1
lonafarnib
1
fluciclovine F-18
1
carmustine, poliferprosan 20 drug combination
1
beta-D-glucosylisophosphoramide mustard
1
azurin (50-77)
1
Tamoxifen
1
Re-Irradiation
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Glioblastoma
×
Magnetic Resonance Spectroscopy
×
Clear all
NCT06319027
2026-05-15
GABLE
Eastern Cooperative Oncology Group
Phase 2
Recruiting
100 enrolled